Baidu
map

Diabetic Med:虚拟援助的生活方式干预对2型糖尿病的作用?

2017-07-06 MedSci MedSci原创

近日,国际杂志 《Diabetic medicine》上在线发表一项关于虚拟援助的生活方式干预在降低印度信息技术行业年轻员工2型糖尿病风险因素方面的功效的一项随机对照试验。调查基于虚拟援助的生活方式干预,以减少印度信息技术行业年轻员工2型糖尿病的风险因素。

近日,国际杂志 《Diabetic medicine》上在线发表一项关于虚拟援助的生活方式干预在降低印度信息技术行业年轻员工2糖尿病风险因素方面的功效的一项随机对照试验。调查基于虚拟援助的生活方式干预,以减少印度信息技术行业年轻员工2糖尿病的风险因素。

LIMIT(信息技术生活方式修正)是一项平行的,部分盲目的随机对照试验。有≥3个危险因素(心脏代谢疾病家族史,超重/肥胖,高血压,空腹血糖异常,高甘油三酯血症,高LDL胆固醇和低HDL胆固醇)的来自两个公司的信息技术行业的员工被随机分配到对照组或干预(11)组。经过初步的生活方式建议,干预小组还通过手机短信(每周三次)和电子邮件(每周两次)进行1年的加强干预。通过意向治疗分析,主要结果是超重/肥胖患病率的变化。

筛查437名员工(平均年龄36.2±9.3;男性74.8%),265人(61.0%)符合条件的,随机对照(n = 132)或干预组(n = 133)。1年后,干预组超重/肥胖患病率下降6.0%,对照组增加6.8%(风险差异11.2; 95CI 1.2-21.1; P = 0.042)。干预组的生活方式指标,腰围,总胆固醇和LDL胆固醇也有显着改善。每例病例治疗/预防的增加成本为1066雷亚尔(112.30英镑)。98%的参与者发现干预可以接受。

基于虚拟援助的生活方式干预在降低信息技术行业年轻员工的糖尿病风险因素方面是有效的,成本效益较高,可接受性也不错,并且具有潜在的扩展性。

原始出处:

T. Limaye, K. Kumaran, C. Joglekar,et al. Efficacy of a virtual assistance-based lifestyle intervention in reducing risk factors for Type 2 diabetes in young employees in the information technology industry in India: LIMIT, a randomized controlled trial

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1637912, encodeId=8816163e912b9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Aug 05 09:19:00 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970509, encodeId=e0fd19e050975, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Thu Jan 25 08:19:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760103, encodeId=1efe1e6010356, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 24 23:19:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607796, encodeId=b082160e7965c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jul 08 01:19:00 CST 2017, time=2017-07-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1637912, encodeId=8816163e912b9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Aug 05 09:19:00 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970509, encodeId=e0fd19e050975, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Thu Jan 25 08:19:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760103, encodeId=1efe1e6010356, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 24 23:19:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607796, encodeId=b082160e7965c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jul 08 01:19:00 CST 2017, time=2017-07-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1637912, encodeId=8816163e912b9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Aug 05 09:19:00 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970509, encodeId=e0fd19e050975, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Thu Jan 25 08:19:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760103, encodeId=1efe1e6010356, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 24 23:19:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607796, encodeId=b082160e7965c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jul 08 01:19:00 CST 2017, time=2017-07-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1637912, encodeId=8816163e912b9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Sat Aug 05 09:19:00 CST 2017, time=2017-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1970509, encodeId=e0fd19e050975, content=<a href='/topic/show?id=fa5d5919df' target=_blank style='color:#2F92EE;'>#Diabetic#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5919, encryptionId=fa5d5919df, topicName=Diabetic)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8949377, createdName=chenzhuanggui, createdTime=Thu Jan 25 08:19:00 CST 2018, time=2018-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760103, encodeId=1efe1e6010356, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Mon Jul 24 23:19:00 CST 2017, time=2017-07-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607796, encodeId=b082160e7965c, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Sat Jul 08 01:19:00 CST 2017, time=2017-07-08, status=1, ipAttribution=)]

相关资讯

Diabetic Med:有微血管并发症1型糖尿病年轻人皮肤自体荧光更高

近日,国际杂志 《Diabetic medicine》上在线发表一项关于有微血管并发症1型糖尿病年轻人皮肤自体荧光的研究,研究非侵入性皮肤自体荧光(一种先进的糖基末端产物的测量方法)提供与1型糖尿病青少年的微血管并发症的早期标记有关的长期血糖替代测量的可能。

Diabetic Med:2型糖尿病患者血糖控制与常见感染之间有无关联?

近日,国际杂志 《Diabetic medicine》上在线发表一项关于2型糖尿病患者血糖控制与常见感染之间的关联的一项队列研究,调查血糖控制对2型糖尿病患者感染发生率的影响。

Diabetic Med:糖尿病对慢性全身闭塞经皮冠状动脉介入治疗急性结局的影响

近日,国际杂志 《Diabetic medicine》上在线发表一项美国多中心登记册的观察性研究,探讨糖尿病对慢性全身闭塞经皮冠状动脉介入治疗急性结局的影响。

Diabetic Med:使用瑞典无烟烟草(鼻烟)对Ⅱ型糖尿病和成年潜伏性自身免疫性糖尿病(LADA)的风险

已经有研究表明,鼻烟(鼻烟)是一种普遍存在于斯堪的纳维亚尼古丁含量高的无烟烟草制品,它能够增加Ⅱ型糖尿病的风险。然而,之前相关的研究很少且存在矛盾,同时缺乏自身免疫性糖尿病相关的研究。本研究的目的是研究鼻烟使用与Ⅱ型糖尿病及成年潜伏性自身免疫性糖尿病(LADA)的风险之间的关系。

Diabetic Med:妇女们早中期体重控制对于预防未来糖尿病的发展至关重要

近日,国际杂志 《Diabetic medicine》上在线发表一项关于绝经期过渡期间雌二醇和促卵泡激素水平的变化与糖尿病风险之间的关系的研究。

Diabetic Med:吃饭是影响患心脏代谢危险因素?

近日,国际杂志 《Diabetic medicine》上在线发表一项关于晚餐的时间是影响患有糖尿病风险的南亚加拿大人的心脏代谢危险因素的研究,探讨有糖尿病风险的南亚加拿大人吃饭时间(晚饭时间或晚餐时间)与心脏代谢危险因素之间的关系。

Baidu
map
Baidu
map
Baidu
map